Home›Trial›NCT05831111
🔬NCT05831111Phase 1ACTIVE NOT RECRUITING

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Study Summary

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Conditions
Epstein-Barr Virus Infection
Interventions / Drugs
mRNA-1195.1mRNA-1195.2mRNA-1189PlacebomRNA-1195
View on ClinicalTrials.gov ↗
Sponsor
MRNA
Moderna Inc
mRNA Therapeutics
C53/100
Study Details
Enrollment482 participants
Primary Completion—
Lead SponsorModernaTX, Inc.
Data Retrieved2026-04-11 02:55:38.209165+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.